The semantics of translational research
Jason Robert, Arizona State University, USA

Translational medicine: Achievements and challenges
Martin Wehling, University of Heidelberg, Germany 

Coffee

Translational science: Regulatory perspective
Jan Johannessen, FDA, USA

Linking drug discovery to successful products
Stephen Eck, Eli Lilly & Company, USA

Lunch and Poster Viewing

Translation in antiarrhythmic treatment
Jonathan Makielski, University of Wisconsin – Madison, USA

Translational medicine and therapeutics in the lipid arena: Recent successes and
failures
Daniel Rader, University of Pennsylvania School of Medicine, USA

Coffee

Antiatherscleotic therapy beyond aspirin and the statins
Valentin Fuster, Mount Sinai School of Medicine, USA

New oral anticoagulants/antiplatelet agents: translation succeeded
William Fay, University of Missouri, USA

The post-surgery limbo and the need for targeting the initial stages of the metastatic
process
Alessandro Fatatis, Drexel University College of Medicine, USA

Harvesting Nanoparticles: Routine measurement of biomarkers, that were previously impossible due to low abundance or instability
Lance Liotta, George Mason University, USA

Coffee

Tumor imaging in disease diagnosis progress and therapeutic outcome

Case History 1

Case History 2

Challenges in CNS drug discovery
Michael Williams, Cephalon Inc, USA

Imaging in neuroscience drug discovery
Richard Hargreaves, Merck & Co, USA

Biomarkers
Gerard Fox, Abbott, USA

Coffee

Schizophrenia
Joseph Coyle, Harvard, USA

Neurodegenerative disorders: The opportunities and challenges of experimental
therapeutics
Donald Price, Johns Hopkins University School of Medicine, USA

Pain
Gerald Gebhart, University of Pittsburgh School of Medicine, USA

Translational research on addictive disorders
Charles O’Brien, University of Pennsylvania, USA

Participants:
Symposium Chairs, Speakers and Darryle Schoepp, Merck & Co, USA